may have a central role in inflammatory joint diseases as a "fine-tuning" cytokine.
gene polymorphisms are associated with bladder cancer in a Chinese Han population.
The second study assessed ixekizumab (LY2439821), a humanized IgG4 monoclonal antibody that neutralizes interleukin-17
, in 142 patients with moderate to severe plaque psoriasis.
Ensemble Therapeutics, a biotechnology company developing Ensemblins(TM), a novel class of small molecule therapeutics with the power of biologics, announced today that a poster presentation on its orally active small molecule antagonists of Interleukin-17
has been selected for presentation at the American College of Rheumatology (ACR) 2012 Annual Meeting taking place November 9-14, 2012 in Washington, DC.
And for the first time, they found that the physical symptoms experienced by the affected animals were apparently linked to an increase in levels of interleukin-17
(IL-17)-a protein involved in regulating the inflammatory response.
Novel therapies aimed at alternative targets such as interleukin 12/23 (IL-12/23), interleukin-17
(IL-17), interleukin-6 (IL-6), phosphodiesterase type 4 (PDE4) and janus kinase (JAK) are in active development, with a PDE4 inhibitor and an anti-IL-12/23 closest to approval for PsA.
Ensemble Therapeutics, a biotechnology company developing Ensemblins(TM), a novel class of small molecule therapeutics with the power of biologics, announced today that the company has identified a series of unique small molecule antagonists of Interleukin-17
, a pro-inflammatory cytokine implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn's and intestinal bowel disease.
Th17 cells are characterized by the production of interleukin-17
(IL-17), a highly inflammatory cytokine that plays an important role in the pathogenesis of immune-mediated diseases, including psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (colitis) and asthma.
Vidofludimus is a novel oral inhibitor of dihydroorotate dehydrogenase (DHODH) and of pro-inflammatory cytokine release including interleukin-17
(IL-17A and IL-17F) as well as interferon-gamma which is in Phase IIb development for rheumatoid arthritis and has completed a positive Phase IIa study in inflammatory bowel disease.
PLANEGG-MARTINSRIED, Germany -- 4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, has presented novel data on the mechanism of action of vidofludimus, an oral inhibitor of interleukin-17
(IL-17A and IL-17F) release and DHODH.
3, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17
(IL-17) receptor, for the treatment of moderate to severe psoriasis at the 22[sup.
PLANEGG-MARTINSRIED, Germany -- 4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease (IBD) with vidofludimus, an oral inhibitor of interleukin-17
(IL-17) release and DHODH, including the secondary endpoints comprising the analysis of CDAI (Crohn's disease, CD) and CAI (ulcerative colitis, UC) disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.